Jacobson Pharma Corporation Limited
雅各臣科研製藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code : 2633)

POSITIVE PROFIT ALERT

This announcement is made by Jacobson Pharma Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "**Director(s)**") of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the year ended 31 March 2025 ("**FY2025**") and the information currently available to the Board, the Group expects to record an increase of over 40% in the profit from continuing operations for FY2025 compared to that for the year ended 31 March 2024.

The significant increase in profit for the year from continuing operations was primarily driven by promising performance in both the specialty medicines and overall generic drug business, complemented by revenue contributions from newly in-licensed products and the robust launch of new products. Additionally, increased operating leverage across our production facilities and financial savings from effective cost control measures also contributed to the growth.

As a result of the Company no longer consolidating the results of JBM (Healthcare) Limited (stock code: 2161) ("**JBM Healthcare**") and its subsidiaries in the financial statements following the distribution of JBM Healthcare shares to Shareholders as a special dividend in specie in August 2023, the profit attributable to equity shareholders of the Company for FY2025 is expected to increase by over 10% compared to that for the year ended 31 March 2024.

As at the date of this announcement, the consolidated results of the Group for FY2025 have not yet been finalised. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to unaudited consolidated management accounts of the Group for FY2025 and the information currently available to the Board. Such information has not been reviewed and confirmed by the auditor of the Company, and may be subject to adjustments. Further details of the Group's performance will be disclosed in the annual results announcement of the Company for FY2025 in accordance with the Listing Rules, which is expected to be published on 13 June 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jacobson Pharma Corporation Limited
YU Chun Kau
Company Secretary

Hong Kong, 26 May 2025

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Wong Chi Kei, Ian as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Lam Sing Kwong, Simon as independent non-executive Directors.